1. A novel HER2-targeted liposomal formulation reduces the risk of hepatotoxicity induced by PEG-based anticancer drugs. (February 2020) Authors: De Martin, S.; Sarcognato, S.; Gabbia, D.; Canato, E.; Colognesi, M.; Cazzagon, N.; Guido, M.; Pasut, G. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Novel super stealth immunoliposomes for cancer targeted delivery of doxorubicin: an innovative strategy to reduce liver toxicity. (February 2019) Authors: Gabbia, D.; Canato, E.; Carraro, V.; Tomasini, L.; Guido, M.; Pasut, G.; De Martin, S. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Site-selective enzymatic chemistry for polymer conjugation to protein lysine residues: PEGylation of G-CSF at lysine-4. Issue 42 (13th October 2016) Authors: Mero, A.; Grigoletto, A.; Maso, K.; Yoshioka, H.; Rosato, A.; Pasut, G. Journal: Polymer chemistry Issue: Volume 7:Issue 42(2016) Page Start: 6545 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗